DERMATOLOGIC AND OPHTHALMIC DRUGS ADVISORY COMMITTEE

November 16, 2000

Tacrolimus Ointment

NDA 50-777

Briefing Information

Fujisawa Healthcare, Inc.

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Briefing Document

Appendix I-IV

Food & Drug Administration

Briefing Document